

References

I-33

1. De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and over expression of BAFF: Evidence for long-term efficacy. *Clin Exp Rheumatol*. 2014;32(4):490-494.
2. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. *J Rheumatol*. 2014;41(2):300-9.
3. Collins C, Dall'Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSERVE study in the USA. *Lupus Sci Med*. 2016;3(1).
4. Ke X, Eisenberg Lawrence D, Oglesby A, et al. A retrospective administrative claims database evaluation of the utilization of belimumab in US managed care settings. *Clin Ther*. 2015;37(12):2852-63.
5. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: Safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
6. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
7. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
8. MICROMEDEX®SOLUTIONS Compendia. 2019. Belimumab.
9. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. Belimumab.
10. Belimumab (Benlysta) for intravenous or subcutaneous administration [package insert]. Human Genome Sciences, Inc., (a subsidiary of GlaxoSmithKline). Rockville, MD. 2011. Revised 09/2019.
11. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two week randomized, double-blind, placebo-controlled study. *Arthritis Rheumatol*. 2017;69(5):1016–1027.
12. Bangert E, Wakani L, Merchant M, et al. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. *Patient Relat Outcome Meas*. 2019;10:1-7.